← Back to Clinical Trials
Recruiting NCT06928857

NCT06928857 Study on the Effects of an EMG-controlled Functional Electrical Stimulator for Upper Limb for Post-stroke Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06928857
Status Recruiting
Phase
Sponsor Fondazione Don Carlo Gnocchi ETS
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-03-03
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
EMG-based FES rehabilitationTraditional rehabilitation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-03-03 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Upper limb disabilities are among the most debilitating issues after a cerebral stroke. One promising approach in motor rehabilitation is the use of functional electrical stimulation (FES). This technique can be integrated into daily therapy to follow an adaptive approach, exploiting the residual capacities of patients. FES can help to stimulate the affected muscles, improve coordination and strengthen the weakened muscles, thus supporting the rehabilitation process.

Eligibility Criteria

Inclusion Criteria: * 18 years or older * Diagnosis of first ischemic or hemorrhagic unilateral stroke for at least two weeks * Medical Research Council score for at least one upper limb muscle greater than 0 and less than 5 (excluding extremes). * Signed informed consent Exclusion Criteria: * Score at the Mini Mental State Examination (adjusted for age and schooling) \< 24 * Clinical evidence in the case of visual disturbance, ideomotor apraxia, behavioral disorders, neglect, sensory, visual and auditory disturbances of severe degree or otherwise that prevent use of the device * Major head trauma * Cardio-respiratory or internal clinical instability * State of pregnancy or lactation * Severe spasticity (Ashworth \> 3) * Skin integrity problems at the interface surface with the device * Implanted electronic devices * Epilepsy not medically controlled * Severe peripheral neuropathy * Recent interventions * Thrombosis, thrombophlebitis * Active stent carrier less than six months * Severe forms of arteriosclerosis, arterial circulatory disorders * Hypertension not treated * Cardiac arrhythmias * Hemorrhagic disorders (hemophilia) * Severe forms of diabetes mellitus * Known allergy to materials making up the device or its applied parts * Cancer or tumour disease * Acute arthritis * Other neurological diseases other than stroke * Progressive muscular dystrophy * Abdominal or inguinal hernias * Undiagnosed back pain * Diseases of internal organs

Contact & Investigator

Central Contact

Alessandro Viganò, MD, PhD

✉ avigano@dongnocchi.it

📞 00390240308890

Principal Investigator

Maurizio Ferrarin, PhD, Eng

PRINCIPAL INVESTIGATOR

IRCCS Fondazione Don Carlo Gnocchi ONLUS

Frequently Asked Questions

Who can join the NCT06928857 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06928857 currently recruiting?

Yes, NCT06928857 is actively recruiting participants. Contact the research team at avigano@dongnocchi.it for enrollment information.

Where is the NCT06928857 trial being conducted?

This trial is being conducted at Genova, Italy, La Spezia, Italy, Milan, Italy.

Who is sponsoring the NCT06928857 clinical trial?

NCT06928857 is sponsored by Fondazione Don Carlo Gnocchi ETS. The principal investigator is Maurizio Ferrarin, PhD, Eng at IRCCS Fondazione Don Carlo Gnocchi ONLUS. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology